Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miniCHOP + orelabrutinib
- Development stage
- Unknown
- Lead developer
- InnoCare Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
miniCHOP + orelabrutinib is an investigational combination regimen consisting of a reduced-dose chemotherapy backbone (miniCHOP) and the second-generation Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib. It is primarily being evaluated for the treatment of newly diagnosed patients with the MCD subtype of diffuse large B-cell lymphoma (DLBCL). The MCD subtype is characterized by mutations in MYD88 and CD79B, which drive chronic active B-cell receptor signaling, making these tumors sensitive to BTK inhibition. Orelabrutinib is a potent, irreversible, covalent small molecule inhibitor with high selectivity for BTK. The miniCHOP component typically includes cyclophosphamide, doxorubicin, vincristine, and prednisone at reduced doses to improve tolerability, particularly in elderly or frail patients. The regimen is often administered as induction therapy followed by orelabrutinib monotherapy maintenance.
- Other names
- R-miniCHOP + orelabrutinibHi-miniCHOP + orelabrutinibPola-R-miniCHP + orelabrutinib
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on miniCHOP + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miniCHOP + orelabrutinib.